Zydus Lifesciences Limited (ZYDUSLIFE)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q1 FY27 consolidated revenue ₹80.2bn +22% y-y; EBITDA ₹19.3bn, margin 24.1%; PAT ₹9.4bn
- India branded formulations grew 20% y-y, outperforming market in chronic and super-specialty therapies
- International formulations revenue ₹9.7bn +34% y-y; North America revenue ₹31bn, US generics filings and launches strong
- Consumer wellness revenue ₹14.3bn +67% y-y; international business +25%, domestic skin & hair care +35%
- US branded business now 10% of US revenue; specialty and innovation portfolio scaling, Saroglitazar NDA under review
- Capex guidance ₹1,500-1,600 Cr for FY27; investments in SEZ expansion, R&D, CAR-T, vaccines
- EBITDA margin guidance maintained at 24%+ despite Saro investment ramp-up in H2 FY27
- Multiple analyst queries on US branded growth, Saro launch timeline, biosimilars scale-up, and Assertio acquisition impact
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ZYDUSLIFE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ZYDUSLIFE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Zydus Lifesciences Limited
Important.
The summary above is generated automatically from Zydus Lifesciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.